SG10201911616QA - Individualized vaccines for cancer - Google Patents

Individualized vaccines for cancer

Info

Publication number
SG10201911616QA
SG10201911616QA SG10201911616QA SG10201911616QA SG10201911616QA SG 10201911616Q A SG10201911616Q A SG 10201911616QA SG 10201911616Q A SG10201911616Q A SG 10201911616QA SG 10201911616Q A SG10201911616Q A SG 10201911616QA SG 10201911616Q A SG10201911616Q A SG 10201911616QA
Authority
SG
Singapore
Prior art keywords
cancer
individualized vaccines
individualized
vaccines
Prior art date
Application number
SG10201911616QA
Inventor
Ugur Sahin
Sebastian Kreiter
Mustafa Diken
Jan Diekmann
Michael Koslowski
Cedrik Britten
John Castle
Martin Löwer
Bernhard Renard
Tana Omokoko
Graaf Johannes Hendrikus De
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of SG10201911616QA publication Critical patent/SG10201911616QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
SG10201911616QA 2011-05-24 2012-05-23 Individualized vaccines for cancer SG10201911616QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
EP2012000006 2012-01-02

Publications (1)

Publication Number Publication Date
SG10201911616QA true SG10201911616QA (en) 2020-01-30

Family

ID=46148823

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013070727A SG193553A1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer
SG10201911616QA SG10201911616QA (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013070727A SG193553A1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Country Status (22)

Country Link
US (3) US10738355B2 (en)
JP (5) JP6444171B2 (en)
CN (3) CN111286537A (en)
AU (4) AU2012261237B2 (en)
BR (1) BR112013029834A8 (en)
CA (1) CA2836494C (en)
DK (2) DK3892295T3 (en)
ES (3) ES2746233T3 (en)
FI (1) FI3892295T3 (en)
HR (2) HRP20230443T1 (en)
HU (3) HUE057608T2 (en)
LT (3) LT3892295T (en)
MX (2) MX360823B (en)
NZ (2) NZ730355A (en)
PL (1) PL3892295T3 (en)
PT (3) PT3892295T (en)
RS (2) RS64230B1 (en)
RU (1) RU2670745C9 (en)
SG (2) SG193553A1 (en)
SI (2) SI3473267T1 (en)
WO (1) WO2012159754A2 (en)
ZA (1) ZA201306944B (en)

Families Citing this family (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
SG195652A1 (en) 2008-11-07 2013-12-30 Sequenta Inc Methods of monitoring conditions by sequence analysis
HUE029424T2 (en) 2009-01-15 2017-02-28 Adaptive Biotechnologies Corp Adaptive immunity profiling and methods for generation of monoclonal antibodies
JP2012531202A (en) 2009-06-25 2012-12-10 フレッド ハチンソン キャンサー リサーチ センター How to measure adaptive immunity
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531671A (en) 2010-10-01 2015-04-22 现代治疗公司 Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
AU2012261237B2 (en) 2011-05-24 2017-06-01 BioNTech SE Individualized vaccines for cancer
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
EP2768982A4 (en) 2011-10-21 2015-06-03 Adaptive Biotechnologies Corp Quantification of adaptive immune cell genomes in a complex mixture of cells
EP2788509B1 (en) 2011-12-09 2018-07-11 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
ES2923757T3 (en) 2011-12-16 2022-09-30 Modernatx Inc Modified mRNA compositions
AU2013226081B2 (en) 2012-02-27 2018-06-14 Becton, Dickinson And Company Compositions and kits for molecular counting
EP2823060B1 (en) 2012-03-05 2018-02-14 Adaptive Biotechnologies Corporation Determining paired immune receptor chains from frequency matched subunits
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DK2831276T3 (en) 2012-05-08 2016-08-01 Adaptive Biotechnologies Corp Compositions and Methods for Measuring and Calibrating Amplification Bias in Multiplex PCR Reactions
CA2879024A1 (en) * 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
LT2901341T (en) * 2012-09-28 2019-09-25 The University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
ES2749118T3 (en) 2012-10-01 2020-03-19 Adaptive Biotechnologies Corp Assessment of immunocompetence for adaptive immunity receptor diversity and clonality characterization
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
EP2925348B1 (en) * 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014093186A1 (en) * 2012-12-12 2014-06-19 Garvin Alex M Non-invasive detection of colorectal neoplasia using circular consensus sequencing
US9128861B2 (en) 2013-01-17 2015-09-08 Personalis, Inc. Methods and systems for genetic analysis
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
KR20150132479A (en) * 2013-03-15 2015-11-25 어댑티브 바이오테크놀로지스 코포레이션 Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
AU2014251207B2 (en) * 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
WO2015013461A2 (en) * 2013-07-26 2015-01-29 Sequenta, Inc. Cancer vaccination with antigen evolution
WO2015031691A1 (en) 2013-08-28 2015-03-05 Cellular Research, Inc. Massively parallel single cell analysis
WO2015031689A1 (en) 2013-08-30 2015-03-05 Personalis, Inc. Methods and systems for genomic analysis
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051275A1 (en) 2013-10-03 2015-04-09 Personalis, Inc. Methods for analyzing genotypes
CN105745528A (en) 2013-10-07 2016-07-06 赛卢拉研究公司 Methods and systems for digitally counting features on arrays
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
DK3077539T3 (en) * 2013-12-02 2018-11-19 Personal Genome Diagnostics Inc Procedure for evaluating minority variations in a sample
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015085233A1 (en) * 2013-12-06 2015-06-11 The Broad Institute Inc. Formulations for neoplasia vaccines
CN106456724A (en) 2013-12-20 2017-02-22 博德研究所 Combination therapy with neoantigen vaccine
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
EP4023249A1 (en) 2014-04-23 2022-07-06 ModernaTX, Inc. Nucleic acid vaccines
CA2960834A1 (en) 2014-09-10 2016-03-17 Genentech, Inc. Immunogenic mutant peptide screening platform
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
EP4026913A1 (en) 2014-10-30 2022-07-13 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
US11066705B2 (en) 2014-11-25 2021-07-20 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP3766988B1 (en) * 2015-02-19 2024-02-14 Becton, Dickinson and Company High-throughput single-cell analysis combining proteomic and genomic information
AU2016222788B2 (en) 2015-02-24 2022-03-31 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
EP3261605B2 (en) 2015-02-26 2022-04-20 SiO2 Medical Products, Inc. Cycloolefin polymer container with a scratch resistant and anti-static coating
ES2836802T3 (en) 2015-02-27 2021-06-28 Becton Dickinson Co Spatially addressable molecular barcodes
ES2934982T3 (en) 2015-03-30 2023-02-28 Becton Dickinson Co Methods for encoding with combinatorial barcodes
AU2016242967B2 (en) 2015-04-01 2021-07-01 Adaptive Biotechnologies Corp. Method of identifying human compatible T cell receptors specific for an antigenic target
WO2016172373A1 (en) 2015-04-23 2016-10-27 Cellular Research, Inc. Methods and compositions for whole transcriptome amplification
ES2836273T3 (en) * 2015-04-27 2021-06-24 Cancer Research Tech Ltd Cancer treatment method
CA2984643A1 (en) * 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
TWI806815B (en) 2015-05-20 2023-07-01 美商博德研究所有限公司 Shared gata3-related tumor-specific neoantigens
WO2016196229A1 (en) 2015-06-01 2016-12-08 Cellular Research, Inc. Methods for rna quantification
TW202241500A (en) * 2015-06-09 2022-11-01 美商博德研究所有限公司 Formulations for neoplasia vaccines and methods of preparing thereof
EP3328394A4 (en) * 2015-07-30 2019-03-13 ModernaTX, Inc. Concatemeric peptide epitope rnas
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
JP6940484B2 (en) 2015-09-11 2021-09-29 セルラー リサーチ， インコーポレイテッド Methods and compositions for library normalization
WO2017062513A1 (en) 2015-10-05 2017-04-13 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP3362103A4 (en) 2015-10-12 2020-02-05 Nantomics, LLC Compositions and methods for viral cancer neoepitopes
CA3003304A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Viral neoepitopes and uses thereof
CN114404581A (en) * 2015-10-22 2022-04-29 摩登纳特斯有限公司 Cancer vaccine
TWI765875B (en) 2015-12-16 2022-06-01 美商磨石生物公司 Neoantigen identification, manufacture, and use
CN105349533A (en) * 2015-12-21 2016-02-24 生工生物工程（上海）股份有限公司 Method for constructing strand-specific transcriptome library
KR20180100659A (en) * 2016-01-08 2018-09-11 백시바디 에이에스 Therapeutic anti-cancer neo-epitope vaccine
EP3400005A1 (en) * 2016-01-08 2018-11-14 Vaccibody AS Neoepitope rna cancer vaccine
EP3475434A4 (en) 2016-03-24 2020-07-29 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
US20190343942A1 (en) * 2016-04-22 2019-11-14 Curevac Ag Rna encoding a tumor antigen
JP7129343B2 (en) 2016-05-02 2022-09-01 ベクトン・ディキンソン・アンド・カンパニー Accurate molecular barcoding
CA3022924A1 (en) * 2016-05-04 2017-11-09 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
JP7046007B2 (en) 2016-05-26 2022-04-01 ベクトン・ディキンソン・アンド・カンパニー How to adjust the molecular label count
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
EP3463440A4 (en) * 2016-05-27 2020-04-15 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
US10640763B2 (en) 2016-05-31 2020-05-05 Cellular Research, Inc. Molecular indexing of internal sequences
EP3484503A1 (en) * 2016-07-13 2019-05-22 Vaximm AG Process for the production of a dna vaccine for cancer immunotherapy
IL264203B1 (en) * 2016-07-20 2024-04-01 Biontech Rna Pharmaceuticals Gmbh Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
SG11201901733PA (en) 2016-09-26 2019-04-29 Cellular Res Inc Measurement of protein expression using reagents with barcoded oligonucleotide sequences
US11608497B2 (en) 2016-11-08 2023-03-21 Becton, Dickinson And Company Methods for cell label classification
CN109952612B (en) 2016-11-08 2023-12-01 贝克顿迪金森公司 Method for classifying expression profiles
WO2018089637A1 (en) 2016-11-11 2018-05-17 Nantbio, Inc. Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
CN108090325B (en) * 2016-11-23 2022-01-25 中国科学院昆明动物研究所 Method for analyzing single cell sequencing data by applying beta-stability
ES2961580T3 (en) 2017-01-13 2024-03-12 Cellular Res Inc Hydrophilic coating of fluid channels
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
WO2018136664A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
NZ755780A (en) * 2017-02-01 2023-10-27 Modernatx Inc Rna cancer vaccines
CN110382708A (en) 2017-02-01 2019-10-25 赛卢拉研究公司 Selective amplification is carried out using blocking property oligonucleotides
BR112019015797A2 (en) * 2017-02-01 2020-03-17 Modernatx, Inc. IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS THAT CODE ACTIVATING ONCOGEN MUTATION PEPTIDES
SI3580561T1 (en) * 2017-02-12 2024-04-30 Biontech Us Inc. Hla-based methods and compositions and uses thereof
WO2018183888A2 (en) 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
MA48047A (en) 2017-04-05 2020-02-12 Modernatx Inc REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
JP7051898B2 (en) 2017-04-24 2022-04-11 ナントセル，インコーポレイテッド Targeted neoepitope vector and method for it
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
EP3621629A4 (en) * 2017-05-11 2021-03-17 Theralase Biotech Inc. Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
US10676779B2 (en) 2017-06-05 2020-06-09 Becton, Dickinson And Company Sample indexing for single cells
WO2018224166A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7334124B2 (en) 2017-06-21 2023-08-28 トランジェーヌ Personalized vaccine
IL271965B2 (en) * 2017-07-12 2023-03-01 Nouscom Ag Neoantigen vaccine composition for treatment of cancer
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
EP3694532A4 (en) 2017-10-10 2021-07-14 Gritstone Oncology, Inc. Neoantigen identification using hotspots
JP2021503897A (en) * 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド Reduced junction epitope presentation for nascent antigens
US20200354730A1 (en) * 2017-11-27 2020-11-12 Nantcell, Inc. Improved Yeast Polytope Vaccine Compositions And Methods
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
TWI727232B (en) * 2017-12-01 2021-05-11 大陸商上海桀蒙生物技術有限公司 Preparation method of personalized cancer vaccine
EP3728642A4 (en) * 2017-12-18 2021-09-15 Personal Genome Diagnostics Inc. Machine learning system and method for somatic mutation discovery
TW201930340A (en) 2017-12-18 2019-08-01 美商尼恩醫療公司 Neoantigens and uses thereof
US11946095B2 (en) 2017-12-19 2024-04-02 Becton, Dickinson And Company Particles associated with oligonucleotides
JP2021509823A (en) 2018-01-04 2021-04-08 アイコニック セラピューティクス インコーポレイテッド Anti-tissue factor antibody, antibody drug conjugate, and related methods
EP3766075A1 (en) * 2018-03-14 2021-01-20 Koninklijke Philips N.V. System and method using local unique features to interpret transcript expression levels for rna sequencing data
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
EP3788171B1 (en) 2018-05-03 2023-04-05 Becton, Dickinson and Company High throughput multiomics sample analysis
US11365409B2 (en) 2018-05-03 2022-06-21 Becton, Dickinson And Company Molecular barcoding on opposite transcript ends
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
CN112261947A (en) * 2018-05-25 2021-01-22 威斯塔研究所 Tumor specific neoantigens and methods of use thereof
CN108897986B (en) * 2018-05-29 2020-11-27 中南大学 Genome sequence splicing method based on protein information
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
WO2020006242A1 (en) * 2018-06-27 2020-01-02 Modernatx, Inc. Personalized cancer vaccine epitope selection
US11639517B2 (en) 2018-10-01 2023-05-02 Becton, Dickinson And Company Determining 5′ transcript sequences
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CN114573688A (en) * 2018-10-19 2022-06-03 杭州纽安津生物科技有限公司 Universal polypeptide vaccine and application thereof in preparation of medicine for treating/preventing pancreatic cancer
JP2022506839A (en) * 2018-11-07 2022-01-17 モデルナティエックス インコーポレイテッド RNA cancer vaccine
WO2020097315A1 (en) 2018-11-08 2020-05-14 Cellular Research, Inc. Whole transcriptome analysis of single cells using random priming
JP7477888B2 (en) * 2018-11-15 2024-05-02 ノイスコム アーゲー Selection of cancer mutations for the generation of personalized cancer vaccines
WO2020123384A1 (en) 2018-12-13 2020-06-18 Cellular Research, Inc. Selective extension in single cell whole transcriptome analysis
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CN113474840A (en) * 2018-12-21 2021-10-01 百欧恩泰美国公司 Methods and systems for predicting HLA class II specific epitopes and characterizing CD4+ T cells
US11371076B2 (en) 2019-01-16 2022-06-28 Becton, Dickinson And Company Polymerase chain reaction normalization through primer titration
ES2945227T3 (en) 2019-01-23 2023-06-29 Becton Dickinson Co Antibody Associated Oligonucleotides
CN113396230A (en) 2019-02-08 2021-09-14 豪夫迈·罗氏有限公司 Methods of diagnosis and treatment of cancer
CN113412120A (en) * 2019-02-15 2021-09-17 Rjan控股公司 Autologous cancer tumor-associated extrachromosomal circular DNA as therapeutic vaccine
CN113557298A (en) 2019-03-13 2021-10-26 东洋纺株式会社 Nucleic acid generation and amplification
US11965208B2 (en) 2019-04-19 2024-04-23 Becton, Dickinson And Company Methods of associating phenotypical data and single cell sequencing data
KR20220016137A (en) 2019-05-30 2022-02-08 그릿스톤 바이오, 인코포레이티드 modified adenovirus
CN112011833B (en) * 2019-05-30 2024-04-26 上海桀蒙生物技术有限公司 Method for screening and isolating tumor neoantigens
EP4004231A1 (en) 2019-07-22 2022-06-01 Becton, Dickinson and Company Single cell chromatin immunoprecipitation sequencing assay
CN110277135B (en) * 2019-08-10 2021-06-01 杭州新范式生物医药科技有限公司 Method and system for selecting individualized tumor neoantigen based on expected curative effect
TWI793451B (en) * 2019-09-20 2023-02-21 納維再生科技股份有限公司 Personalized cancer immunotherapy
EP4055160B1 (en) 2019-11-08 2024-04-10 Becton Dickinson and Company Using random priming to obtain full-length v(d)j information for immune repertoire sequencing
CN112795647B (en) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) Tumor marker and application thereof
MX2022007158A (en) 2019-12-13 2022-07-11 Genentech Inc Anti-ly6g6d antibodies and methods of use.
CN115244184A (en) 2020-01-13 2022-10-25 贝克顿迪金森公司 Methods and compositions for quantifying protein and RNA
EP4117717A1 (en) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
WO2021189047A2 (en) 2020-03-20 2021-09-23 Codiak Biosciences, Inc. Extracellular vesicles for therapy
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
EP4150118A1 (en) 2020-05-14 2023-03-22 Becton Dickinson and Company Primers for immune repertoire profiling
US20230203477A1 (en) 2020-05-26 2023-06-29 The Broad Institute, Inc. Nucleic acid artificial mini-proteome libraries
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
JP2023541108A (en) 2020-08-06 2023-09-28 グリットストーン バイオ インコーポレイテッド Multi-epitope vaccine cassette
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US20240082389A1 (en) 2020-09-23 2024-03-14 Lonza Sales Ag Methods of producing extracellular vesicles
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
EP4247967A1 (en) 2020-11-20 2023-09-27 Becton, Dickinson and Company Profiling of highly expressed and lowly expressed proteins
JP2024501482A (en) 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド Tissue-specific antigens for cancer immunotherapy
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023025404A1 (en) 2021-08-24 2023-03-02 BioNTech SE In vitro transcription technologies
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2023085232A1 (en) 2021-11-10 2023-05-19 東洋紡株式会社 Improved library preparation method
CN114181287B (en) * 2021-12-10 2023-09-19 商丘美兰生物工程有限公司 Preparation method of DNA virus vaccine
CN114350800B (en) * 2021-12-29 2024-03-19 中南大学湘雅医院 Application of SPHK1 in preparation of PD-L1/PD-1 monoclonal antibody tumor immunotherapy medicament
CN114410778B (en) * 2021-12-29 2024-03-19 中南大学湘雅医院 Application of PF543 in preparation of PD-L1/PD-1 monoclonal antibody tumor immunotherapy medicament
KR20230130804A (en) * 2022-03-04 2023-09-12 (주)큐리진 Adenovirus type 5/3 for detecting ctc
EP4253550A1 (en) 2022-04-01 2023-10-04 GenCC GmbH 6 Co. KG Method for the manufacture of a viral system, a vector system or any transport system for cancer-specific crispr complexes
WO2023209068A1 (en) 2022-04-28 2023-11-02 Carbocalyx Gmbh Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
WO2024063788A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024064931A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
ATE220718T1 (en) * 1996-04-19 2002-08-15 Us Gov Sec Health MUTATED RAS PEPTIDES TO GENERATE CD8+ CYTITOXIC T LYMPHOICYTES
DE69723434T2 (en) 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden METHOD FOR SELECTION AND PRODUCTION OF T-CELL PEPTIDE EPITOPE AND VACCINE WITH THIS EPITOPE
DE69717661T2 (en) 1996-09-13 2003-09-25 Lipoxen Technologies Ltd liposome composition
JP2001509135A (en) * 1996-10-11 2001-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cancer immunotherapy using tumor cells combined with mixed lymphocytes
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
JP2001522603A (en) 1997-11-06 2001-11-20 ロシュ ダイアグノスティックス ゲーエムベーハー Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
WO1999034014A2 (en) 1997-12-23 1999-07-08 Roche Diagnostics Gmbh A method for the determination of a nucleic acid
WO1999034015A2 (en) * 1997-12-24 1999-07-08 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
JP2002526421A (en) 1998-10-05 2002-08-20 ジェンザイム・コーポレーション Genes for cancer vaccine design differentially expressed in cancer cells
KR100922809B1 (en) 1999-05-06 2009-10-21 웨이크 포리스트 유니버시티 Compositions And Methods For Identifying Antigens Which Elicit An Immune Response
CA2384987A1 (en) 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides
CA2388045C (en) * 1999-10-20 2014-02-11 Tzyy-Choou Wu Nucleic acid immunogenic compositions encoding hsp-antigen chimera
JP5640237B2 (en) 1999-11-30 2014-12-17 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド Isolated nucleic acid molecule encoding a cancer-associated antigen, the antigen itself and uses thereof
ATE366582T1 (en) 1999-12-28 2007-08-15 Pharmexa Inc OPTIMIZED MINIGENES AND PEPTIDES ENCODED THEM
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2412026A1 (en) 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
ES2454640T3 (en) 2000-08-03 2014-04-11 Johns Hopkins University Molecular vaccine that carries a chaperone polypeptide from the endoplasmic reticulum to an antigen
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
EP2305699B1 (en) 2001-06-05 2014-08-13 CureVac GmbH Stabilised mRNA with increased G/C content which is optimised for translation in its coded areas for the vaccination against sleeping sickness, leishmaniosis and toxoplasmosis
CN100392087C (en) 2001-11-26 2008-06-04 昆士兰大学 Flavivirus vaccine delivery system
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
AU2003235707A1 (en) 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
WO2003070162A2 (en) * 2002-02-19 2003-08-28 Genzyme Corporation Par-3 compounds for therapy and diagnosis and methods for using same
AU2003218181A1 (en) * 2002-03-15 2003-09-29 Multicell Immunotherapeutics, Inc. Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
ATE438857T1 (en) 2002-06-13 2009-08-15 Merck Patent Gmbh METHOD FOR IDENTIFYING ALLO-ANTIGENS AND THEIR USE FOR CANCER THERAPY AND TRANSPLANTATION
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
DE10335833A1 (en) 2003-08-05 2005-03-03 Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE10344799A1 (en) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
US20080063699A1 (en) 2003-10-15 2008-03-13 Michael Teifel Method of Administering Cationic Liposomes Comprising an Active Drug
DE602004030369D1 (en) 2003-10-24 2011-01-13 Immunaid Pty Ltd THERAPY PROCESS
EP1589030A1 (en) * 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Bob-1 specific T cells and methods to use
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (en) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
DE102004035227A1 (en) 2004-07-21 2006-02-16 Curevac Gmbh mRNA mixture for vaccination against tumor diseases
DE102004057303A1 (en) 2004-11-26 2006-06-01 Merck Patent Gmbh Stable crystal modifications of DOTAP chloride
CA2592972A1 (en) 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
CN109485727A (en) 2005-05-09 2019-03-19 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody
MX2007015942A (en) 2005-07-01 2008-03-07 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1).
EP3611266B1 (en) 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
DE102005041616B4 (en) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanoma associated MHC class I associated oligopeptides and polynucleotides encoding them and their uses
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (en) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency
AU2007220042A1 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
JP2009529878A (en) 2006-03-13 2009-08-27 ベリデックス・エルエルシー Primary cell proliferation
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
DE102006060824B4 (en) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Detection of Individual T Cell Response Patterns Against Tumor-associated Antigens (TAA) in Tumor Patients as a Basis for Individual Therapeutic Vaccination of Patients
WO2008083174A2 (en) 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
DK2170959T3 (en) 2007-06-18 2014-01-13 Merck Sharp & Dohme ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
NZ588183A (en) 2008-03-24 2012-05-25 4Sc Discovery Gmbh Novel substituted imidazoquinolines
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
JP5268444B2 (en) * 2008-06-23 2013-08-21 株式会社日立ハイテクノロジーズ Single molecule real-time sequence device, nucleic acid analyzer, and single molecule real-time sequence method
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
EP2344192A4 (en) 2008-10-11 2013-02-13 Government Of The Usa As Represented By The Secretary Dept Of Health And Human Services Method of making a vaccine
CN102282265B (en) 2008-11-28 2020-07-24 埃默里大学 Methods for treating infectious diseases and tumors
DE102008061522A1 (en) 2008-12-10 2010-06-17 Biontech Ag Use of Flt3 ligand to enhance immune responses in RNA immunization
JP5785168B2 (en) 2009-07-31 2015-09-24 エスリス ゲーエムベーハーｅｔｈｒｉｓ ＧｍｂＨ RNA having a combination of unmodified and modified nucleotides for protein expression
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
CA2797868C (en) 2010-05-14 2023-06-20 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
CN104531671A (en) 2010-10-01 2015-04-22 现代治疗公司 Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
DE102011102734A1 (en) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Device for frothing milk, beverage preparation with this device and method for frothing milk
SI2714071T1 (en) 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
AU2012261237B2 (en) 2011-05-24 2017-06-01 BioNTech SE Individualized vaccines for cancer
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
ES2923757T3 (en) 2011-12-16 2022-09-30 Modernatx Inc Modified mRNA compositions
US20150030576A1 (en) 2012-01-10 2015-01-29 Moderna Therapeutics, Inc. Methods and compositions for targeting agents into and across the blood-brain barrier
EP3072898A1 (en) 2012-02-20 2016-09-28 Universita' degli Studi di Milano Homo- and heterodimeric smac mimetic compounds as apoptosis inducers
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
CA2879024A1 (en) 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
KR102121086B1 (en) 2012-11-01 2020-06-09 팩터 바이오사이언스 인크. Methods and products for expressing proteins in cells
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc Removal of dna fragments in mrna production process
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3043826A4 (en) 2013-09-13 2017-05-24 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
JP6363179B2 (en) 2013-09-26 2018-07-25 バイオンテック アーゲー Particles containing RNA shells
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US20160264614A1 (en) 2013-10-02 2016-09-15 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
WO2015085318A2 (en) 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Targeted adaptive vaccines
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CA2938700A1 (en) 2014-02-05 2015-08-13 Biontech Ag A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
EP4023249A1 (en) 2014-04-23 2022-07-06 ModernaTX, Inc. Nucleic acid vaccines
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
PT3708668T (en) 2014-12-12 2022-09-14 Curevac Ag Artificial nucleic acid molecules for improved protein expression
MX2017008670A (en) 2014-12-30 2017-10-11 Curevac Ag Artificial nucleic acid molecules.
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell

Also Published As

Publication number Publication date
ES2746233T8 (en) 2020-03-13
AU2012261237B2 (en) 2017-06-01
HUE057608T2 (en) 2022-06-28
JP7297715B2 (en) 2023-06-26
AU2022201275A1 (en) 2022-03-17
PL3892295T3 (en) 2023-07-24
JP2020128423A (en) 2020-08-27
US20210164034A1 (en) 2021-06-03
LT2714071T (en) 2019-10-10
RU2013157150A (en) 2015-06-27
DK2714071T3 (en) 2019-09-16
ES2946072T3 (en) 2023-07-12
LT3473267T (en) 2021-11-25
JP6444171B2 (en) 2018-12-26
PT2714071T (en) 2019-09-30
CA2836494C (en) 2023-01-03
HRP20211595T1 (en) 2022-01-21
JP2023083289A (en) 2023-06-15
CN103608033B (en) 2016-06-15
AU2019229434B2 (en) 2021-12-16
CN103608033A (en) 2014-02-26
JP2017018129A (en) 2017-01-26
PT3892295T (en) 2023-06-01
NZ718326A (en) 2020-05-29
US20140178438A1 (en) 2014-06-26
ES2746233T3 (en) 2020-03-05
JP6456888B2 (en) 2019-01-23
US20220282322A1 (en) 2022-09-08
JP2014523406A (en) 2014-09-11
FI3892295T3 (en) 2023-05-10
DK3892295T3 (en) 2023-05-15
SG193553A1 (en) 2013-10-30
PT3473267T (en) 2021-11-02
HRP20230443T1 (en) 2023-09-15
JP2019050831A (en) 2019-04-04
CA2836494A1 (en) 2012-11-29
AU2012261237A1 (en) 2013-11-14
HUE046152T2 (en) 2020-02-28
WO2012159754A3 (en) 2013-06-27
NZ730355A (en) 2022-10-28
US10738355B2 (en) 2020-08-11
RU2670745C2 (en) 2018-10-25
CN105999250B (en) 2020-03-10
AU2017213515B2 (en) 2019-07-04
MX360823B (en) 2018-11-16
ES2897656T3 (en) 2022-03-02
HUE062102T2 (en) 2023-09-28
SI3473267T1 (en) 2022-01-31
WO2012159754A2 (en) 2012-11-29
NZ617217A (en) 2016-04-29
RS64230B1 (en) 2023-06-30
RU2670745C9 (en) 2018-12-13
RS62497B1 (en) 2021-11-30
ZA201306944B (en) 2015-02-25
CN105999250A (en) 2016-10-12
MX2013013659A (en) 2014-02-27
SI3892295T1 (en) 2023-09-29
AU2019229434A1 (en) 2019-10-03
CN111286537A (en) 2020-06-16
BR112013029834A8 (en) 2022-10-18
NZ742420A (en) 2022-10-28
US11248264B2 (en) 2022-02-15
LT3892295T (en) 2023-07-10
MX2020011767A (en) 2020-11-24
BR112013029834A2 (en) 2016-12-06
AU2017213515A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
ZA201306944B (en) Individualized vaccines for cancer
HK1197182A1 (en) Cancer immunotherapy
EP2714073A4 (en) In situ antigen-generating cancer vaccine
PL2758630T3 (en) Adjustable fracturing system
HK1199448A1 (en) Disubstituted 5-fluoro-pyrimidines 5--
IL231043A0 (en) Vaccine
GB201120860D0 (en) Cancer immunotherapy
GB201119999D0 (en) Vaccine
HK1201176A1 (en) Antigen presenting cancer vaccine
EP2763699A4 (en) Vaccine
HK1202070A1 (en) Vaccine for tumor immunotherapy
ZA201306245B (en) Combination vaccines
EP2771453A4 (en) Diatom-based vaccines
PL3473267T3 (en) Individualized vaccines for cancer
PL2729158T3 (en) Vaccines for chlamydia
GB201120000D0 (en) Vaccine
GB201107549D0 (en) Cancer vaccine
GB201108984D0 (en) Vaccines
GB201108982D0 (en) Vaccines
GB201108986D0 (en) Vaccines
GB201121647D0 (en) Vaccine
GB201108256D0 (en) Vaccine